New drug shows promise in shrinking lung tumors before surgery
NCT ID NCT07359040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and why. About 80 participants will join this research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?